Third Harmonic Bio to Participate in the 44th Annual TD Cowen Health Care Conference
26. Februar 2024 16:00 ET
|
Third Harmonic Bio
SAN FRANCISCO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today...
Third Harmonic Bio Appoints Christopher Murphy as Chief Financial and Business Officer and Provides Business Update
04. Januar 2024 08:00 ET
|
Third Harmonic Bio
Chris brings extensive enterprise-level leadership experience in business development, commercial operations, and corporate strategy IND-enabling toxicology studies of THB335 nearing completion;...
Third Harmonic Bio Announces Third Quarter 2023 Financial Results
09. November 2023 08:30 ET
|
Third Harmonic Bio
On track to file a U.S. Investigational New Drug (IND) application for THB335 and initiate clinical studies in 1H’24 Strong financial position with cash and cash equivalents totaling $273.9...
Third Harmonic Bio Announces Leadership Changes
31. Oktober 2023 08:30 ET
|
Third Harmonic Bio
SAN FRANCISCO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today...
Third Harmonic Bio to Participate in the Morgan Stanley Global Healthcare Conference
31. August 2023 08:30 ET
|
Third Harmonic Bio
SAN FRANCISCO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today...
Third Harmonic Bio Announces Second Quarter 2023 Financial Results
10. August 2023 08:10 ET
|
Third Harmonic Bio
Introduced next-generation oral KIT inhibitor product candidate THB335, which retains the potency and selectivity of first-generation oral KIT inhibitor, THB001, with differentiated metabolic,...
Third Harmonic Bio Announces Next-Generation Oral KIT Inhibitor Product Candidate THB335
25. Juli 2023 08:30 ET
|
Third Harmonic Bio
THB335 retains selectivity and potency of first-generation oral KIT inhibitor, THB001, with differentiated metabolic, distribution and physicochemical profile THB001 demonstrated evidence of...
Third Harmonic Bio Announces First Quarter 2023 Financial Results
11. Mai 2023 17:00 ET
|
Third Harmonic Bio
SAN FRANCISCO, May 11, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today...
Third Harmonic Bio Announces Fourth Quarter and Year-End 2022 Financial Results
29. März 2023 08:05 ET
|
Third Harmonic Bio
SAN FRANCISCO, March 29, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today...
Third Harmonic Bio Announces Discontinuation of Phase 1b Study of THB001 in Chronic Inducible Urticaria
15. Dezember 2022 07:00 ET
|
Third Harmonic Bio
-- Company decision follows observation of asymptomatic liver transaminitis in two subjects enrolled in first dose cohort of 200mg BID -- Evidence of clinical activity observed; full data set to be...